ReviewBiochemical genetics2026
Influence of Genetic and Epigenetic Factors on Periodontitis Susceptibility and Treatment Outcomes.
Review in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis (PD) is a complex inflammatory condition driven by the interplay of microbial, genetic, epigenetic, and environmental factors. While bacterial biofilms are regarded as the primary cause, growing evidence underscores the significant role of genetic predisposition in determining susceptibility to the disease, its progression, and treatment outcomes. This review explores the genetic polymorphisms of PD, focusing on genes related to inflammatory mediators, immune responses, antimicrobial peptides, matrix metalloproteinases, and vitamin D receptor pathways. Key epigenetic mechanisms including DNA methylation, histone modifications, non-coding RNAs, and emerging RNA methylation pathways are explored in their roles in modulating inflammation, tissue destruction, bone metabolism, and interactions between the host and microbes. Advances in transcriptomic technologies, particularly RNA sequencing, have enhanced our ability to identify molecular biomarkers and cell-specific gene expression profiles associated with disease severity and responses to treatment. The potential for leveraging genetic and epigenetic profiling presents an exciting avenue for personalized periodontal care, including the use of epigenetic therapies targeting pathways involved in inflammation and tissue regeneration. Nonetheless, the current body of evidence has limitations. These include significant variability across studies, inconsistent disease classification systems, small sample sizes, and a predominance of preclinical or exploratory research. Many biomarkers and therapeutic targets proposed to date require further validation before they can be routinely applied in clinical practice. While integrating genetic, epigenetic, transcriptomic, and clinical data holds promise for advancing precision periodontology, rigorous large-scale, and multicenter studies are essential to confirm clinical applicability, validate biomarkers, and facilitate their incorporation into evidence-based treatment protocols.
Indexed as
Identifiers
42477251What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.